|[December 20, 2013]
Symphogen Announces the Appointment of Annika Espander Jansson as Non-Executive Director
COPENHAGEN, Denmark --(Business Wire)--
Symphogen A/S, a private biopharmaceutical company with leadership in
recombinant antibody mixtures for therapeutic use, today announces the
appointment of Annika Espander Jansson as a Non-Executive Director of
the Board, with effect from 19 December 2013.
Annika has over twenty years' experience in the healthcare sector, both
as a sell-side analyst and investor. She has a proven track record in
strategic development of businesses and broad experience in managing
operations in different segments of the financial markets.
Annika began her career as Equity Analyst and Sector Head of Healthcare
at Aros Securities in Stockholm 1994-1996, followed by similar roles at
Enskilda Securities, where she was Sector Head of Equity Research in
Healthcare for five years, and Handelsbanken Capital Markets, where she
gained experience of the financial services sector and became Group Head
of Private Banking. She joined Catella Healthcare, a private venture
capital investor in healthcare companies, in 2004 as Managing Partner of
a small team of professionals, during which time the IRR of the
company's portfolio exceeded 35%. Annika returned to Handelsbanken as
Global Head o Private Banking in September 2010-June 2013 during which
time the bank's ranking was upgraded to No. 1, according to the
influential client survey - Prospera.
Annika is currently the founder and CEO of Asperia, a strategic and
business advisory firm in the healthcare and financial services sectors.
She is also a Board member of the public companies Stille AB and Probi
AB, private portfolio companies Attana AB, Cellartis AB and Duocort AB,
as well as the Swedish Financial Analyst Organisation. Annika holds a
Ph.D. from the University of Gothenburg.
Welcoming the appointment, Gôran Ando MD, Chairman of the Board,
commented: "I am delighted to welcome Annika to Symphogen. Annika's
extensive experience in both the healthcare industry and financial
markets makes her a perfect addition to the Board. Annika's skills,
knowledge and experience will be invaluable to furthering the success of
Annika Espander Jansson added: "I am very excited to take part in
the development of Symphogen which operates in a very important medical
area with significant unmet medical needs and with a business concept
aiming at improving therapies for cancer patients."
About Symphogen A/S
Symphogen is developing next-generation antibody therapeutics for the
treatment of cancer and is dedicated to bringing truly innovative
oncology products to the market.
The company has advanced the frontier of antibody discovery by creating
well-characterized antibody mixtures that address multiple oncology
targets in a single drug product. The company has matured its oncology
pipeline and has currently brought two product candidates into the
clinic. The company's productive technology suite - capable of
identifying, selecting and manufacturing optimal antibody mixtures -
fuels Symphogen's innovative pipeline.
The lead oncology product, Sym004, was out-licensed to Merck KGaA in
2012 following phase 2 clinical data in late stage cancer patients.
In total, the company has raised €249 million in equity capital from
premier international investors including Novo, Essex Woodlands Health
Ventures and PKA, and employs 95 people, most of whom are based at
Symphogen's facilities in Copenhagen.
[ Back To Technology News's Homepage ]